GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannapharmarx Inc (OTCPK:CPMD) » Definitions » EV-to-EBIT

Cannapharmarx (Cannapharmarx) EV-to-EBIT : -4.09 (As of May. 10, 2024)


View and export this data going back to 1999. Start your Free Trial

What is Cannapharmarx EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Cannapharmarx's Enterprise Value is $22.43 Mil. Cannapharmarx's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-5.48 Mil. Therefore, Cannapharmarx's EV-to-EBIT for today is -4.09.

The historical rank and industry rank for Cannapharmarx's EV-to-EBIT or its related term are showing as below:

CPMD' s EV-to-EBIT Range Over the Past 10 Years
Min: -5.2   Med: 0   Max: 0
Current: -4.09

CPMD's EV-to-EBIT is ranked worse than
100% of 669 companies
in the Drug Manufacturers industry
Industry Median: 17.95 vs CPMD: -4.09

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Cannapharmarx's Enterprise Value for the quarter that ended in Sep. 2023 was $23.18 Mil. Cannapharmarx's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-5.48 Mil. Cannapharmarx's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -23.64%.


Cannapharmarx EV-to-EBIT Historical Data

The historical data trend for Cannapharmarx's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cannapharmarx EV-to-EBIT Chart

Cannapharmarx Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -42.98 -3.48 -1.88 -1.52 -3.18

Cannapharmarx Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.93 -3.18 -3.65 -3.43 -4.23

Competitive Comparison of Cannapharmarx's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Cannapharmarx's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cannapharmarx's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cannapharmarx's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cannapharmarx's EV-to-EBIT falls into.



Cannapharmarx EV-to-EBIT Calculation

Cannapharmarx's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=22.430/-5.479
=-4.09

Cannapharmarx's current Enterprise Value is $22.43 Mil.
Cannapharmarx's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.48 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cannapharmarx  (OTCPK:CPMD) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Cannapharmarx's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2023 ) =EBIT / Enterprise Value (Q: Sep. 2023 )
=-5.479/23.17671
=-23.64 %

Cannapharmarx's Enterprise Value for the quarter that ended in Sep. 2023 was $23.18 Mil.
Cannapharmarx's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.48 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cannapharmarx EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Cannapharmarx's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Cannapharmarx (Cannapharmarx) Business Description

Traded in Other Exchanges
N/A
Address
888 3rd Street SW, Suite 3600, Calgary, AB, CAN, T2P 5C5
Cannapharmarx Inc is involved in the cannabis sector. The company negotiates, acquires, and develops various cannabis cultivation projects throughout Canada. Its three projects include the Hanover Project; the Great Northern Project; and the Acquisition of Sunniva Medical.
Executives
Anthony Michael Panek director 95 SOUTH STATE STREET, SUITE 2300, SALT LAKE CITY UT 84111
Dominic Colvin director, officer: Chief Executive Officer C/O CANNAPHARMARX, INC., 2 PARK PLAZA, SUITE 1200-B, IRVINE CA 92614
John Hamilton Cassels officer: Chief Financial Officer SUITE 500, 209 8TH AVENUE SW, CALGARY A0 T2P 1B8
Richard Dale Orman director 302, 3204 RIDEAU PLACE SW, CALGARY A0 T2S1Z2
Andrew Clifford Steedman officer: Chief Operating Officer 1131 RIVERDALE AVE SW, CALGARY A0 T2S 0Y9
Marc R Branson director 977 KEITH ROAD, WEST VANCOUVER A1 V7T 1M6
Gary J Herick 10 percent owner 7609 RALSTON ROAD, ARVADA CO 80002
James F Samuelson director PO BOX 22, NEWPORT BEACH CA 92662
Matthew Nicosia director, 10 percent owner 2 PARK PLAZA, SUITE 400, IRVINE CA 92614
Robert M Liess director 2602 W. SAM ALLEN RD., PLANT CITY FL 33565
Mathew D Sherwood director P.O. BOX 4375, DILLON CO 80435
James E Smeeding director 4029 GILBERT AVENUE, DALLAS TX 75219
Elie M Khalife director 9447 E. CROSS CREEK STREET, WICHITA KS 67206
Steven J Rule director C/O CANNAPHARMARX, INC., ONE COLLINS DRIVE, SUITE 100, CARNEYS POINT NJ 08069
Alexander R Giaquinto director 120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920